Patient dosing in Nymox Pharmaceutical's multi-center phase II clinical trial of NX-1207 for the treatment of benign prostatic hyperplasia has been completed.
Subscribe to our email newsletter
To date, regular reviews of safety data for the trial have revealed no serious drug side effects from NX-1207 treatment. The Independent Data Monitoring Committee for the trial recently gave a positive recommendation based on evaluation of the efficacy and safety data then available.
Two earlier completed phase I and II trials of NX-1207 showed that the drug produced on average over 23% prostate shrinkage and significant symptomatic improvement in 1 month with minimal side effects. Overall there were no sexual side effects, and a better side effect profile compared to existing drugs.
Follow-up of patients from these trials have shown continued significant symptomatic improvement 29-34 months after initial treatment.
Benign prostatic hyperplasia (BHP) afflicts approximately half of men over age 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems.